NCT00905424 - Exploratory Study of SPD489 in Adults With Major Depressive Disorder (MDD) as Augmentation Therapy to an Antidepressant | Biotech Hunter

Enrollment

246

Participants

Timeline

Start Date

July 30, 2009

Primary Completion Date

August 4, 2010

Study Completion Date

August 4, 2010

Conditions

Major Depressive Disorder

Interventions

DRUG

Antidepressant + SPD489 (lisdexamfetamine dimesylate)

Escitalopram oxalate (antidepressant) 20 mg/day oral + 20, 30, or 50 mg SPD489 oral once daily for 6 weeks

DRUG

Antidepressant + placebo

Escitalopram oxalate (antidepressant) 20 mg/day oral + placebo oral once daily for 6 weeks

Trial Locations (15)

27705

Duke University Medical Center, Durham

30080

Carman Research, Smyrna

30328

Atlanta Institute of Medicine & Research, Atlanta

32809

Clinical Neuroscience Solutions, Inc., Orlando

33912

Gulfcoast Clinical Research Center, Fort Myers

34208

Florida Clinical Research Center, LLC, Bradenton

44130

North Star Medical Research, LLC, Middleburg Heights

66212

Vince & Associates Clinical Research, Overland Park

73103

IPS Research Company, Oklahoma City

78756

FutureSearch Clinical Trials, LP, Austin

92108

Affiliated Research Institute, San Diego

92660

Pharmacology Research Institute (PRI), Newport Beach

97210

Summit Research Network, Portland

98007

Northwest Clinical Research Center, Bellevue

98104

Summit Research Network (Seattle), LLC, Seattle